Indivior Pharmaceuticals, Inc Q2 2026 Earnings: Beat on EPS and Revenue

Indivior Pharmaceuticals, Inc (INDV) delivered a strong earnings beat for Q2 2026, reporting adjusted earnings per share of $0.96 versus analyst estimates of $0.67, representing a 43.69% positive surprise. The addiction treatment specialist also exceeded revenue expectations, posting $317.0 million compared to the $278.3 million consensus estimate, a 13.91% beat.

Indivior develops and commercializes treatments for substance use disorders, with its flagship product Sublocade, a monthly injectable buprenorphine formulation for opioid use disorder, driving the majority of its revenue alongside oral buprenorphine-naloxone products.

The $0.96 EPS represents a significant improvement from the $0.52 reported in Q2 2025, marking an 84.6% year-over-year increase. This quarter’s performance also exceeded the $0.81 EPS delivered in Q1 2026, demonstrating sequential growth momentum.

Revenue of $317.0 million reflected a 22.4% increase compared to Q2 2025’s $259.1 million, with Sublocade sales contributing $198.2 million, up 28.7% year-over-year. The company’s oral buprenorphine-naloxone products generated $87.4 million in revenue, while international markets contributed $31.4 million to the quarterly total.

Gross margin expanded to 87.2% from 84.1% in the prior-year quarter, driven by improved manufacturing efficiencies and favorable product mix. Operating expenses increased 12.8% to $156.3 million, primarily due to higher research and development investments of $34.7 million and increased commercial spending of $89.1 million.

For Q3 2026, Indivior raised its full-year revenue guidance to a range of $1.24 billion to $1.28 billion, up from the previous range of $1.18 billion to $1.22 billion. The company also increased its adjusted EBITDA guidance to $420 million to $450 million, reflecting confidence in sustained demand for its addiction treatment portfolio.

Analysts at Jefferies raised their price target to $28 from $24 following the results, citing stronger-than-expected Sublocade uptake and expanding market penetration. Cantor Fitzgerald maintained its overweight rating while increasing its revenue estimates for 2026 and 2027 by 8% and 6%, respectively.

Shares of INDV gained 7.3% in after-hours trading to $23.45, building on the stock’s 34.2% year-to-date advance. The pharmaceutical sector has seen increased investor interest in addiction treatment companies as healthcare systems focus on addressing the ongoing opioid crisis.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.